Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Brilaroxazine

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Reviva to Participate in Chat by AGP on Brilaroxazine’s Potential
    Reviva to Participate in Chat by AGP on Brilaroxazine’s Potential

    23 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/23/3279835/0/en/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazine-s-potential-across-multiple-neuropsychiatric-indications.html

    GLOBENEWSWIRE
    23 Apr 2026
    Share Share
    Reviva Unveils 2025 Financials & Business Updates
    Reviva Unveils 2025 Financials & Business Updates

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264432/0/en/Reviva-Reports-Full-Year-2025-Financial-Results-and-Recent-Business-Highlights.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Reviva Shares RECOVER Ph3 Data on Schizophrenia Negative Symptoms
    Reviva Shares RECOVER Ph3 Data on Schizophrenia Negative Symptoms

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215319/0/en/Reviva-Announces-Publication-on-Clinical-Vocal-Biomarker-Data-from-the-RECOVER-Phase-3-Clinical-Trial-of-Brilaroxazine-to-Treat-Negative-Symptoms-in-Schizophrenia.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    Reviva Updates Brilaroxazine Development For Schizophrenia
    Reviva Updates Brilaroxazine Development For Schizophrenia

    23 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/23/3209836/0/en/Reviva-Announces-Regulatory-Update-Regarding-the-Development-of-Brilaroxazine-for-the-Treatment-of-Schizophrenia.html

    GLOBENEWSWIRE
    23 Dec 2025
    Share Share
    Reviva Secures EU Patent for Brilaroxazine in Pulmonary Fibrosis
    Reviva Secures EU Patent for Brilaroxazine in Pulmonary Fibrosis

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184521/0/en/Reviva-Announces-Grant-of-European-Patent-Covering-Use-of-Brilaroxazine-for-the-Treatment-of-Pulmonary-Fibrosis.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    Reviva Presents Brilaroxazine Ph 3 Schizophrenia Data at CNS 2025
    Reviva Presents Brilaroxazine Ph 3 Schizophrenia Data at CNS 2025

    28 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/28/3175313/0/en/Reviva-to-Present-Negative-Symptom-Data-for-Brilaroxazine-in-Schizophrenia-from-the-Phase-3-RECOVER-Double-Blind-and-Open-Label-Extension-Trials-at-the-CNS-Summit-2025.html

    GLOBENEWSWIRE
    28 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.